Study Results Confirm Higher Sensitivity of T-SPOT ® .TB in Immunosuppressed Patient Groups Oxford, UK; 15 March 2006 - Oxford Immunotec Ltd, the T cell measurement company has today announced the outcome of a recent study completed by a group in Milan demonstrating the sensitivity of T-SPOT.
Oxford Immunotec Announces Further Strengthening of Senior Management Team Oxford, UK; 27 February 2006 - Oxford Immunotec Ltd, the T cell measurement company, has announced a number of appointments to its Senior Management Team. Philip Page has been appointed as Director, Operations with effect
Oxford Immunotec's T-SPOT ® .TB is First Test to Demonstrate Accurate Diagnosis of Latent TB in HIV Patients Oxford, UK; 6 February 2006 - Oxford Immunotec Ltd, the Company that monitors T cells for the diagnosis and treatment of disease, today announced the results of a study published
Oxford Immunotec Announces Launch of Second Generation Product Based on Co-Development with Millipore Oxford, UK and Billerica, MA, USA; 31 January 2006 - Oxford Immunotec Ltd, today announced the launch of a second generation product, T-SPOT ® .
UK Nurses and General Public Reject Introduction of 115-Year-Old Tuberculosis (TB) Test Oxford, UK; 27 January 2006 - 70% of TB nurses think the introduction of the outdated Mantoux skin test for detecting latent TB infection is a step backwards, with more than a third believing it is a major
Oxford Immunotec Wins Medical Futures Innovation Award Oxford, UK; 4 November 2005 - Oxford Immunotec's revolutionary new blood test for diagnosing TB infection, called T-SPOT™. TB has won the Equinox-sponsored award for the Best Business Proposition at the Medical Futures Innovation Awards
Millipore and Oxford Immunotec Co-develop Plates for Diagnosing and Monitoring Infections Billererica, MA, USA and Oxford, UK, 21 September 2005 - Millipore Corporation (NYSE:MIL) and Oxford Immunotec Ltd. announced today the co-development of a specially designed microtitre plate for use in
Oxford Immunotec Closes £7M in Series B Financing Oxford, UK; 3 August 2005 - Oxford Immunotec, the T cell diagnostics company, announced today that it has closed a £7M series B private equity financing. The round was led by Prelude Ventures, who invested £2.75M, alongside Quester,
Oxford Immunotec Prevails in Core Patent Dispute with Cellestis and Sanofi-Pasteur Oxford, UK; 11 July 2005 - Oxford Immunotec, the T-cell diagnostics company, announced today that its core patent, number 0941478, has been upheld by the European Patent Office (EPO).